Why This Procedure Exists
Every new pharmaceutical compound must be assessed for cardiovascular risk before human trials. The heart is the organ most likely to produce fatal adverse drug reactions. ICH guidelines S7A (2000) and S7B (2005) established the framework: test the drug in a conscious animal with implanted telemetry to measure heart rate, blood pressure, and cardiac electrical activity in real time.
This single procedure is one of the primary reasons beagles remain in laboratories. No validated alternative exists.
The Surgical Implantation
Under general anesthesia, a transmitter device (roughly the size of a deck of cards) is implanted in the dog's abdomen or flank. From this device, wires are tunneled subcutaneously:
Surgery: 1-3 hours. Recovery: ~3 weeks (Elizabethan collar, suture monitoring, complication watch). Dogs may be reused across multiple studies.
Baseline Physiology
QT prolongation is associated with fatal cardiac arrhythmias in humans. Any statistically significant deviation from baseline is flagged as a safety signal.
The False-Negative Problem
The model reliably detects high-potency hERG channel blockers but misses drugs that cause QT prolongation through other mechanisms, at clinical concentrations, or through metabolites not formed in dogs. Some drugs flag positive in dogs but show no cardiac effect in humans, terminating potentially safe therapies.
This failure rate is published in peer-reviewed literature and acknowledged by the FDA. The requirement persists because no single replacement has been validated to regulatory satisfaction.
The Path Forward: CiPA
ICH S7B was revised in 2022 to allow greater use of in vitro and in silico approaches. The Comprehensive In Vitro Proarrhythmia Assay (CiPA) initiative aims to replace dog telemetry by combining human ion channel assays, computational modeling, and human stem cell-derived cardiomyocytes. Progress has been slow. For now, regulators continue to expect dog cardiovascular data for most new drug applications.